These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16223812)
1. Women with early breast cancer to be tested for trastuzumab treatment. Mayor S BMJ; 2005 Oct; 331(7521):864. PubMed ID: 16223812 [No Abstract] [Full Text] [Related]
2. Sucked into the Herceptin maelstrom. Keidan J BMJ; 2007 Jan; 334(7583):18. PubMed ID: 17204797 [No Abstract] [Full Text] [Related]
3. Herceptin: HERalding a new era in breast cancer care but at what cost? Hutchinson L; DeVita VT Nat Clin Pract Oncol; 2005 Dec; 2(12):595. PubMed ID: 16341094 [No Abstract] [Full Text] [Related]
4. Trastuzumab for early breast cancer. Smith IE Lancet; 2006 Jan; 367(9505):107. PubMed ID: 16413866 [No Abstract] [Full Text] [Related]
5. Herceptin and early breast cancer: a moment for caution. Lancet; 2005 Nov; 366(9498):1673. PubMed ID: 16291043 [No Abstract] [Full Text] [Related]
6. A "bureausceptic" view of cancer drug rationing. Crown J Lancet; 2001 Nov; 358(9294):1660. PubMed ID: 11728537 [No Abstract] [Full Text] [Related]
7. Patient takes her fight for trastuzumab to the High Court. Dyer C BMJ; 2006 Feb; 332(7537):320. PubMed ID: 16470035 [No Abstract] [Full Text] [Related]
8. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article. ; Burgess EP N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207 [No Abstract] [Full Text] [Related]
9. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. Lewis R; Bagnall AM; Forbes C; Shirran E; Duffy S; Kleijnen J; Riemsma R; ter Riet G Health Technol Assess; 2002; 6(13):1-71. PubMed ID: 12137722 [No Abstract] [Full Text] [Related]
10. Trastuzumab for early breast cancer: evolution or revolution? Littlejohns P Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378 [No Abstract] [Full Text] [Related]
11. Trastuzumab in the adjuvant treatment of breast cancer. Svetlovska D; Mardiak J; Kristova V Bratisl Lek Listy; 2007; 108(2):100-3. PubMed ID: 17685010 [TBL] [Abstract][Full Text] [Related]
12. British clinic is allowed to deny medicine; decision on cost has broad impact. Lyall S N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743 [No Abstract] [Full Text] [Related]
13. Trastuzumab for early breast cancer raises important issues. Wilson EC BMJ; 2005 Oct; 331(7523):1023. PubMed ID: 16254311 [No Abstract] [Full Text] [Related]
14. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Garnock-Jones KP; Keating GM; Scott LJ BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285 [No Abstract] [Full Text] [Related]
15. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer]. Heinzl S Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587 [No Abstract] [Full Text] [Related]
16. Trastuzumab for early breast cancer. Bryant J; Geyer CE Lancet; 2006 Mar; 367(9512):728. PubMed ID: 16517268 [No Abstract] [Full Text] [Related]
17. NICE approves trastuzumab for early stage breast cancer. Mayor S BMJ; 2006 Jun; 332(7555):1409. PubMed ID: 16777868 [No Abstract] [Full Text] [Related]
18. Trastuzumab for early breast cancer. Stuart NS; Bishop J; Bale C Lancet; 2006 Jan; 367(9505):107-8. PubMed ID: 16413865 [No Abstract] [Full Text] [Related]
19. Adjuvant trastuzumab for breast cancer. Dent R; Clemons M BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471 [No Abstract] [Full Text] [Related]
20. Monoclonal antibody therapies shine in breast cancer clinical trials. Hampton T JAMA; 2005 Jun; 293(24):2985-9. PubMed ID: 15972551 [No Abstract] [Full Text] [Related] [Next] [New Search]